The senolytic landscape

FOXO4-DRI among its rivals

FOXO4-DRI is one entry in a crowded field of senolytics. One of them, dasatinib plus quercetin, reached small human pilots, and one candidate, UBX0101, did no better than placebo in a placebo-controlled phase 2. A 2026 review says FOXO4-DRI has not been evaluated in human trials. Placing it beside the others shows what is distinctive about it and how far it sits from the clinic.

This unit maps the class, walks through the human pilot data other senolytics have that FOXO4-DRI lacks, and studies two cautionary failures the field learned from.